Heron Therapeutics Inc. (NASDAQ:HRTX)’s share price shot up 5.1% during trading on Tuesday . The company traded as high as $21.87 and last traded at $21.72, with a volume of 336,434 shares trading hands. The stock had previously closed at $20.66.

A number of brokerages have recently commented on HRTX. Jefferies Group reissued a “buy” rating and issued a $46.00 target price on shares of Heron Therapeutics in a research note on Wednesday, July 27th. Cantor Fitzgerald reissued a “buy” rating and issued a $38.00 target price on shares of Heron Therapeutics in a research note on Tuesday, August 9th. Leerink Swann set a $33.00 target price on shares of Heron Therapeutics and gave the company a “buy” rating in a research note on Thursday, August 11th. Cowen and Company reissued a “buy” rating on shares of Heron Therapeutics in a research note on Saturday, July 9th. Finally, Brean Capital reissued a “buy” rating and issued a $55.00 target price on shares of Heron Therapeutics in a research note on Saturday, August 13th. One investment analyst has rated the stock with a sell rating, nine have issued a buy rating and one has assigned a strong buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $47.70.

The firm has a 50-day moving average of $18.13 and a 200 day moving average of $18.80.

Heron Therapeutics (NASDAQ:HRTX) last announced its quarterly earnings data on Monday, August 8th. The biotechnology company reported ($1.17) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.96) by $0.21. Analysts expect that Heron Therapeutics Inc. will post ($4.39) EPS for the current fiscal year.

In related news, insider Robert Rosen sold 100,000 shares of the business’s stock in a transaction that occurred on Wednesday, August 10th. The shares were sold at an average price of $23.30, for a total transaction of $2,330,000.00. Following the transaction, the insider now directly owns 102,640 shares of the company’s stock, valued at $2,391,512. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

A hedge fund recently bought a new stake in Heron Therapeutics stock. Bank of Montreal Can acquired a new position in shares of Heron Therapeutics Inc. (NASDAQ:HRTX) during the fourth quarter, according to its most recent filing with the SEC. The fund acquired 112,720 shares of the biotechnology company’s stock, valued at approximately $3,010,000.

Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.